Key result
Various pharmacological interventions have documented beneficial effects on morbidity and mortality across multiple cardiovascular conditions.
The paper discusses the distinction between statistical significance and clinical relevance in the context of major cardiovascular clinical trials.
During the last two decades several large clinical trials have documented beneficial eVects of diVerent pharmacological interventions on morbidity and mortality in various cardiovascular conditions. Based on the results of these trials physicians in general feel convinced that there is a considerable reduction of mortality and morbidity as a result of treatment with: (a) ‚ receptor blockers in patients with acute myocardial infarction as well as in the postinfarction period; (b) acetylsalicylic acid (ASA; aspirin) and thrombolytic drugs in patients with acute myocardial infarction; (c) angiotensin converting enzyme (ACE) inhibitors in patients with left ventricular systolic dysfunction irrespective of symptoms of heart failure and, as recently shown in the HOPE study, in patients with high cardiovascular risk but without heart failure or obvious left ventricular systolic dysfunction; (d) ‚ receptor blockers and spironolactone in addition to an ACE inhibitor in patients with chronic heart failure; (e) diuretics, ‚ receptor blockers, calcium channel blockers, and ACE inhibitors in hypertension; and (f) statins in secondary pre
No takes yet. Share an insight, caveat, or question.
Ronnie Willenheimer (2000) conducted a review in cardiovascular conditions. pharmacological interventions was evaluated. Various pharmacological interventions have documented beneficial effects on morbidity and mortality across multiple cardiovascular conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: